Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of 2,6-Diaminopurine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.63 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.53 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.96 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.96 |
| ▸ | CDK2 | P24941 | 11/20 | 0.63 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.58 |
| ▸ | PI4KA | P42356 | 2/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 10/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.53 |
| ▸ | MGMT | P16455 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL24053 | 0.98 | PDPK1 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.96 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.96 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.94 | PDPK1 (0.92) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8079030 | 0.89 | PDPK1 (0.77) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL1033682 | 0.89 | PDPK1 (0.82) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL4535059 | 0.87 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL13857840 | 0.87 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL30680639 | 0.87 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL3238169 | 0.87 | PDPK1 (0.79) | PDPK1GDACDK2DPP4MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0615856-B1 | Recording sheets containing tetrazolium, indolinium, imidazole and imidazolinium compounds | XEROX CORP (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0456817-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | ASH STEVENS INC (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5296589-A | Dissolving in nonreactive solvent, reacting with hydrogen, palladium chloride, hydrochloric acid in sealed vessel at elevated pressure, removing palladium chloride, neutralizing, separating product | ASH STEVENS, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5110919-A | Economical preparation of nucleosides | ASH STEVENS, INC. (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0456817-A4 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | — | 1992-04-22 | — | — | EP | disclosed |
| EP-0456817-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES. | ASH STEVENS INC (US) | 1991-11-21 | — | — | EP | disclosed |
| WO-1991008215-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-9-(2,3,5-TRI-0-BENZYL-BETA-D-ARABINOFURANOSYL)ADENINE AND NOVEL INTERMEDIATES | ASH STEVENS, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0072027-B1 | ANTIVIRAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-05-18 | — | — | EP | disclosed |
| EP-0072027-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-02-16 | — | — | EP | disclosed |
| US-4360522-A | VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1982-11-23 | — | — | US | disclosed |
| US-4323573-A | VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1982-04-06 | — | — | US | disclosed |
| US-4294831-A | ANTIVIRAL ACTIVITY | BURROUGHS WELLCOME CO. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4199574-A | Methods and compositions for treating viral infections and guanine acyclic nucleosides | BURROUGHS WELLCOME CO. (US) | 1980-04-22 | — | — | US | disclosed |
| US-4146715-A | ANTIVIRAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1979-03-27 | — | — | US | disclosed |